Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: metacrine.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/22/2021 | $2.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 10/22/2021 | $19.00 → $1.00 | Buy → Hold | Canaccord Genuity |
| 10/22/2021 | $14.00 → $2.00 | Buy → Hold | Jefferies |
| 10/22/2021 | Buy → Neutral | HC Wainwright & Co. |
15-12G - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
S-8 POS - Metacrine, Inc. (0001634379) (Filer)
S-8 POS - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)
EFFECT - Metacrine, Inc. (0001634379) (Filer)
25-NSE - Metacrine, Inc. (0001634379) (Subject)
DEF 14A - Metacrine, Inc. (0001634379) (Filer)
8-K - Metacrine, Inc. (0001634379) (Filer)